JinIX Foundation Marks a New Chapter with a Partner Event at Its Retreat Center
JinIX Foundation retreat brings partners together through art, etiquette, wellness, and community while celebrating a new home for meaningful connection...
Day: March 10, 2026
Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program
2026 program to highlight nurse leadership and excellence in clinical innovation, patient-centered care, culture & retention, and care team communication...
Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program
2026 program to highlight nurse leadership and excellence in clinical innovation, patient-centered care, culture & retention, and care team communication...
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern...
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
— The new pricing structure is made available as of February for 26,63 DKK per day at pharmacies throughout Denmark...
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
— The new pricing structure is made available as of February for 26,63 DKK per day at pharmacies throughout Denmark...
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks...
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks...
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW...
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW...
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical...
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical...
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company),...
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company),...
HealthEdge HealthRules® Payer Works with AWS to Set a New Scalability Benchmark, Expanding to Support Health Plans with More Than 40 Million Members
Platform advancements running on AWS position HealthEdge customers to meet future healthcare demands and growthBOSTON, March 10, 2026 (GLOBE NEWSWIRE)...
HealthEdge HealthRules® Payer Works with AWS to Set a New Scalability Benchmark, Expanding to Support Health Plans with More Than 40 Million Members
Platform advancements running on AWS position HealthEdge customers to meet future healthcare demands and growthBOSTON, March 10, 2026 (GLOBE NEWSWIRE)...
Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection
WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Egg Medical, a leader in enhanced radiation protection devices (ERPD), today announced the...